Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.17 (
CaMKII
)
4,029
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The calcium/
calmodulin-dependent kinase II
(
CaMKII
) participates with Ras to Raf-1 activation, and it is necessary for activation of the extracellular signal-regulated kinase (ERK) by different factors in epithelial and mesenchimal cells. Raf-1 activation is a complex multistep process, and its maximal activation is achieved by phosphorylation at Y341 by Src and at S338 by other kinase/s. Although early data proposed the involvement of
p21-activated kinase 3
(Pak3), the kinase phosphorylating S338 remains to be definitively identified. In this study, we verified the hypothesis that
CaMKII
phosphorylates Raf-1 at Ser338. To do so, we determined the role of
CaMKII
in Raf-1 and ERK activation by oncogenic Ras and other factors. Serum, fibronectin, Src (Y527) and Ras (V12) activated
CaMKII
and ERK, at different extents. The inhibition of
CaMKII
attenuated Raf-1 and ERK activation by all these factors.
CaMKII
was also necessary for the phosphorylation of Raf-1 at S338 by serum, fibronectin and Ras. Conversely, inhibition of Pak3 activation by blocking phosphatidylinositol 3-kinase was ineffective. The direct phosphorylation of S338 Raf-1 by
CaMKII
was demonstrated in vitro by interaction of purified kinases. These results demonstrate that Ras activates
CaMKII
, which, in turn, phosphorylates Raf-1 at S338 and participates in ERK activation upon different stimuli.
...
PMID:Calcium/calmodulin-dependent protein kinase II (CaMKII) phosphorylates Raf-1 at serine 338 and mediates Ras-stimulated Raf-1 activation. 2259 32